Personalized Medicine – Products

HiFi data generated on the Revioä system will support the EU and Estonian government-funded Center for Personalized Medicine and unlock discoveries across cardiology, mental and reproductive health, drug response, cancer research and rare diseases.

In this article, Mark Lawler, professor of digital health, answers your questions about these revolutionary techniques and discusses the barriers to their implementation in the clinic. Prof. Lawler has an international reputation in cancer research and a focus on developing a molecular understanding of cancer to improve patient care, including through precision medicine.

Study demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies. Proteograph Product Suite enables scalable deep, unbiased proteomics by mass spectrometry.

Tecan is announcing a streamlined solution portfolio to enable liquid biopsy applications, from upstream workflows to downstream analysis for genomics and proteomics applications.

The project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN trial. The Assay will be available as a service in the Babraham Institute’s Flow Cytometry Facility.

Research partnership aims to build strong pharma and academic collaborations in sharing data and clinical samples to develop biomarker-based diagnostics for Alzheimer’s Disease.

PlaqueTec announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Oligonucleotide therapeutics (OTs) show great promise in the field of personalized medicine as a method of targeting undruggable proteins.